These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8994768)

  • 21. Effect of tissue penetration on AmBisome efficacy.
    Adler-Moore J; Proffitt RT
    Curr Opin Investig Drugs; 2003 Feb; 4(2):179-85. PubMed ID: 12669379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The experience is CLEAR.
    Chandrasekar P
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients.
    Annaloro C; Olivares C; Usardi P; Onida F; Della Volpe A; Tagliaferri E; Deliliers GL
    J Antimicrob Chemother; 2009 Mar; 63(3):625-6. PubMed ID: 19158110
    [No Abstract]   [Full Text] [Related]  

  • 24. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.
    O'Horo JC; Osmon DR; Abu Saleh OM; Marcelin JR; Gharaibeh KA; Hamadah AM; Barwise AK; Kayhart BM; McDonald JS; McDonald RJ; Leung N
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
    J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B].
    van't Wout JW; Novakova I; Verhagen CA; Fibbe WE; de Pauw BE; van der Meer JW
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():11-3. PubMed ID: 1663200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J; Markham L; Matulionyte R; Rives V; Lew D
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in renal function after changes in antifungal drug therapy.
    Klibanov OM; Raasch RH; Rublein JC
    Am J Health Syst Pharm; 2004 Jan; 61(1):50-3. PubMed ID: 14725121
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases].
    Jia L; Huang M; Liu WL; Zhang YC; Sun HY; Zhang DH; Deng JN; Zhou JF
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):619-22. PubMed ID: 19175991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R
    Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
    [No Abstract]   [Full Text] [Related]  

  • 34. [Resolution of a disseminated infection by Fusarium solani in a patient with acute promyelocytic leukemia and granulocytopenia secondary to chemotherapy by the combined use of G-CSF and liposomal amphotericin B].
    Sancho JM; Ribera JM; Matas L; Batlle M
    Med Clin (Barc); 1997 Jun; 109(4):156-7. PubMed ID: 9289532
    [No Abstract]   [Full Text] [Related]  

  • 35. Disseminated Penicillium marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B.
    Wang JL; Hung CC; Chang SC; Chueh SC; La MK
    Transplantation; 2003 Oct; 76(7):1136-7. PubMed ID: 14557769
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.
    Clemons KV; Sobel RA; Williams PL; Stevens DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Must we be really concerned about amphotericin B toxicity in oncology patients?].
    Mayer J; Doubek M
    Cas Lek Cesk; 1998 Oct; 137(20):632-6. PubMed ID: 9863267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies.
    Schulenburg A; Sperr W; Rabitsch W; Knöbl P; Thalhammer F
    Leuk Lymphoma; 2005 Aug; 46(8):1163-7. PubMed ID: 16085557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.